These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26249025)

  • 41. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy.
    Wong GL; Wong VW
    World J Gastroenterol; 2013 Oct; 19(39):6515-22. PubMed ID: 24151375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.
    Yang HI; Yuen MF; Chan HL; Han KH; Chen PJ; Kim DY; Ahn SH; Chen CJ; Wong VW; Seto WK;
    Lancet Oncol; 2011 Jun; 12(6):568-74. PubMed ID: 21497551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
    Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
    Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis B virus DNA in patients with hepatitis B-related liver cirrhosis with or without hepatocellular carcinomas: a matched case-control study.
    Xu J; Lin Y; Wang YP; Chen YX; Shi B; Lu J; Xie WF
    J Dig Dis; 2009 May; 10(2):138-44. PubMed ID: 19426397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiviral therapy and long-term outcome for hepatitis B virus-related hepatocellular carcinoma after curative liver resection in a Japanese cohort.
    Sakamoto K; Beppu T; Hayashi H; Nakagawa S; Okabe H; Nitta H; Imai K; Hashimoto D; Chikamoto A; Isiko T; Kikuchi K; Baba H
    Anticancer Res; 2015 Mar; 35(3):1647-55. PubMed ID: 25750323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan).
    Jung KS; Kim SU; Ahn SH; Park YN; Kim DY; Park JY; Chon CY; Choi EH; Han KH
    Hepatology; 2011 Mar; 53(3):885-94. PubMed ID: 21319193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
    Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
    J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B.
    Chon YE; Jung ES; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Jung KS; Kim SU
    J Clin Gastroenterol; 2012 Jul; 46(6):518-25. PubMed ID: 22688146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. APS (Age, Platelets, 2D Shear-Wave Elastography) Score Predicts Hepatocellular Carcinoma in Chronic Hepatitis B.
    Zhang T; Zhang G; Deng X; Zeng J; Jin J; Zeping H; Wu M; Zheng R
    Radiology; 2021 Nov; 301(2):350-359. PubMed ID: 34427463
    [TBL] [Abstract][Full Text] [Related]  

  • 50. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis.
    Wu S; Kong Y; Piao H; Jiang W; Xie W; Chen Y; Lu L; Ma A; Xie S; Ding H; Shang J; Zhang X; Feng B; Han T; Xu X; Huo L; Cheng J; Li H; Wu X; Zhou J; Sun Y; Ou X; Zhang H; You H; Jia J
    Liver Int; 2018 Jun; 38(6):1045-1054. PubMed ID: 29119705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. What can we learn from hepatitis B virus clinical cohorts?
    Lin CL; Tseng TC; Kao JH
    Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B.
    Kamalapirat T; Yingcharoen K; Ungtrakul T; Soonklang K; Dechma J; Chunnuan P; Kusuman P; Pothijaroen C; Tawpa J; Cheirsilpa K; Auewarakul C
    J Viral Hepat; 2021 Jul; 28(7):1034-1041. PubMed ID: 33880807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study.
    Dan JQ; Zhang YJ; Huang JT; Chen MS; Gao HJ; Peng ZW; Xu L; Lau WY
    Eur J Surg Oncol; 2013 Aug; 39(8):865-72. PubMed ID: 23597497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis].
    Kim MJ; Kwon OS; Chung NS; Lee SY; Jung HS; Park DK; Ku YS; Kim YK; Kim YS; Kim JH
    Korean J Hepatol; 2008 Mar; 14(1):67-76. PubMed ID: 18367859
    [TBL] [Abstract][Full Text] [Related]  

  • 55. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy.
    Lee HW; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
    Liver Int; 2019 Sep; 39(9):1624-1630. PubMed ID: 31050379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Validation study of prediction models of hepatitis B virus-related hepatocellular carcinoma].
    Chen W; Chen J; Zheng Q; Dong J; You J; Yuan P; Zhu Y; Liu YR; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Jul; 23(7):507-11. PubMed ID: 26398841
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
    Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
    J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy.
    Song IH; Kim SM; Choo YK
    World J Gastroenterol; 2013 Dec; 19(47):8867-72. PubMed ID: 24379609
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Progressive increase of serum circulating immune complexes and its significance in patients during the progression from chronic hepatitis B to hepatocellular carcinoma].
    Du J; Tian P; Chen TY; Wu JX; Wang JB; Wei Y; Wang LM; Liu LG; Ji WS; Qu CF
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):905-10. PubMed ID: 22340099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.